Jon and others, question 

Apabetalone reduces circulating ACE2 protein levels in patients, and downregulates ACE2 gene transcription by 40-90% in vitro

Do we know how long it takes to reduce ACE2 receptors once treatment starts?  Remember in early 13 week test it was 4 to 5 weeks before usable HDL cells began showing.  Not much help with Type2 and COVID-19.  They may not have that much time.  Just my thought, (could be all wrong), if test begins when Type 2 patient shows signs of COVID, will ABL have the desired affect, if ABL takes time to ramp up?

This is for our sicentists, I have no idea, just questions.  Thanks, sidebar.

Another thought, if ABL does take 4 to 5 weeks and shows signs of benefit, seems to reason Type 2 should begin ABL treatment before exposure to COVID.  Benefit to RVX now.